ASTM F2313-2008e1 Standard Specification for Poly(glycolide) and Poly(glycolide-co-lactide) Resins for Surgical Implants with Mole Fractions Greater Than or Equal to 70 % Glycolide.pdf

1、Designation: F 2313 081Standard Specification forPoly(glycolide) and Poly(glycolide-co-lactide) Resins forSurgical Implants with Mole Fractions Greater Than orEqual to 70 % Glycolide1This standard is issued under the fixed designation F 2313; the number immediately following the designation indicate

2、s the year oforiginal adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. Asuperscript epsilon () indicates an editorial change since the last revision or reapproval.1NOTESection 9.1 was editorially corrected in January 2009

3、.1. Scope1.1 This specification covers both virgin poly(glycolide)resin and poly(glycolide-co-lactide) resin with mole fractionsgreater than or equal to 70 % glycolide. This specification isnot applicable to glycolide:lactide copolymers with molefractions exceeding 30 % lactide.1.2 Since poly(glycol

4、ide) is commonly abbreviated as PGAfor poly(glycolic acid) and poly(lactide) is commonly abbre-viated as PLA for poly(lactic acid), these polymers are com-monly referred to as PGA and PLA:PGA resins for thehydrolytic byproducts to which they respectively degrade.1.3 This specification addresses mate

5、rial characteristics ofboth virgin poly(glycolide) and poly(70 % glycolide-co-lactide) resins intended for use in surgical implants and doesnot apply to packaged and sterilized finished implants fabri-cated from these materials.1.4 As with any material, some characteristics may bealtered by processi

6、ng techniques (such as molding, extrusion,machining, assembly, sterilization, and so forth) required forthe production of a specific part or device. Therefore, proper-ties of fabricated forms of this resin should be evaluatedindependently using appropriate test methods to ensure safetyand efficacy.1

7、.5 The values stated in SI units are to be regarded asstandard. No other units of measurement are included in thisstandard.1.6 This standard may suggest use of hazardous materials,operations, and equipment. This standard does not purport toaddress all of the safety concerns, if any, associated with

8、itsuse. It is the responsibility of the user of this standard toestablish appropriate safety and health practices and deter-mine the applicability of regulatory limitations prior to use.2. Referenced Documents2.1 ASTM Standards:2D 1505 Test Method for Density of Plastics by the Density-Gradient Tech

9、niqueD 2857 Practice for Dilute Solution Viscosity of PolymersD 3417 Test Method for Enthalpies of Fusion and Crystal-lization of Polymers by Differential Scanning Calorimetry(DSC)3D 3418 Test Method for Transition Temperatures and En-thalpies of Fusion and Crystallization of Polymers byDifferential

10、 Scanning CalorimetryD 3536 Test Method for Molecular Weight Averages andMolecular Weight Distribution by Liquid Exclusion Chro-matography (Gel Permeation ChromatographyGPC)3D 3593 Test Method for Molecular Weight Averages andMolecular Weight Distribution of Certain Polymers byLiquid Size-Exclusion

11、Chromatography (Gel PermeationChromatographyGPC) Using Universal Calibration3D 4603 Test Method for Determining Inherent Viscosity ofPoly(Ethylene Terephthalate) (PET) by Glass CapillaryViscometerE 386 Practice for Data Presentation Relating to High-Resolution Nuclear Magnetic Resonance (NMR) Spectr

12、os-copyE 473 Terminology Relating to Thermal Analysis and Rhe-ologyE 793 Test Method for Enthalpies of Fusion and Crystalli-zation by Differential Scanning Calorimetry1This specification is under the jurisdiction of ASTM Committee F04 onMedical and Surgical Materials and Devices and is the direct re

13、sponsibility ofSubcommittee F04.11 on Polymeric Materials.Current edition approved Aug. 1, 2008. Published September 2008. Originallyapproved in 2003. Last previous edition approved in 2003 as F 2313 03.2For referenced ASTM standards, visit the ASTM website, www.astm.org, orcontact ASTM Customer Ser

14、vice at serviceastm.org. For Annual Book of ASTMStandards volume information, refer to the standards Document Summary page onthe ASTM website.3Withdrawn.1Copyright ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States.E 794 Test Method for Melting An

15、d Crystallization Tem-peratures By Thermal AnalysisE 967 Test Method for Temperature Calibration of Differ-ential Scanning Calorimeters and Differential ThermalAnalyzersE 968 Practice for Heat Flow Calibration of DifferentialScanning CalorimetersE 1142 Terminology Relating to Thermophysical Properti

16、esE 1252 Practice for General Techniques for Obtaining In-frared Spectra for Qualitative AnalysisE 1356 Test Method for Assignment of the Glass TransitionTemperatures by Differential Scanning CalorimetryE 1994 Practice for Use of Process Oriented AOQL andLTPD Sampling PlansF 748 Practice for Selecti

17、ng Generic Biological Test Meth-ods for Materials and Devices2.2 Other Standards:United States Pharmacopeia (USP) Edition 264ISO 31-8 Physical Chemistry and Molecular Physics, Part8: Quantities and Units5ISO 11357 PlasticsDifferential Scanning Calorimetry(DSC)5ICH Q3C(R3) International Conference on

18、 Harmonisationof Technical Requirements for Registration of Pharmaceu-ticals for Human Use, Quality Guideline: Impurities:Residual Solvents621 CFR 820, United States Code of Federal Regulations,Title 21Food and Drugs Services, Part 820QualitySystem Regulation7ANSI/ISO/ASQ Q9000-2000, Quality Managem

19、ent Sys-tems; Fundamentals and Vocabulary5ANSI/ISO/ASQ Q9001-2000, Quality Management Sys-tems; Requirements5NIST Special Publication SP811 Guide for the Use of theInternational System of Units (SI)83. Terminology3.1 Definition:3.1.1 virgin polymer, nthe initially delivered form of apolymer as synth

20、esized from its monomers and prior to anyprocessing or fabrication into a medical device.4. Materials and Manufacture4.1 All raw monomer components and other materialscontacting either the raw monomer(s) or resin product shall beof a quality suitable to allow for use of such resin in themanufacture

21、of an implantable medical product. Such qualityincludes adequate control of particles and other potentialcontaminants that may affect either the toxicity of or the cellresponse to the as-implanted or degrading final product.4.2 All polymer manufacturing (including monomer han-dling, synthesis, pelle

22、tization/grinding and all subsequent)shall be undertaken under conditions suitable to allow for useof such resin in the manufacture of an implantable medicalproduct.5. Chemical Composition5.1 Polymers covered by this specification shall be com-posed either of glycolide, or of a combination of glycol

23、ide andlactide where the lactide content does not exceed 30 % molefraction (34.7 % by mass). To ensure such composition and theattainment of the desired properties, the following tests are tobe conducted.5.2 Chemical Identification:5.2.1 The identity of the virgin polymer shall be confirmedeither by

24、 infrared,1H-NMR, or13C-NMR spectroscopy.5.2.2 Infrared Identification:5.2.2.1 Identity of either poly(glycolide) homopolymer orpoly(glycolide-co-lactide) copolymer may be confirmedthrough an infrared spectrum exhibiting major absorptionbands only at the wavelengths that appear in a suitablereferenc

25、e spectrum. Analysis shall be conducted using prac-tices similar to those described in Practice E 1252. A typicalinfrared transmission reference spectrum for PGA homopoly-mer is shown in Fig. 1. A typical infrared transmissionreference spectrum for a 90 % PGA:10 % l-PLA copolymer isshown in Fig. 2.

26、While poly(glycolide-co-lactide) copolymerswill each have their own respective spectrum that will vary inresponse to copolymer ratio, this analytic method typicallylacks sensitivity sufficient for quantification of copolymer ratioas specified in 7.1.2.5.2.2.2 Additional spectral bands may be indicat

27、ive ofknown or unknown impurities, including residual solvents andcatalysts (refer to limits specified in Table 1).5.2.3 Proton Nuclear Magnetic Resonance (1H-NMR) Iden-tification:5.2.3.1 Identity of either poly(glycolide) homopolymer orpoly(glycolide-co-lactide) copolymer may be confirmedthrough sa

28、mple dissolution,1H-NMR spectroscopy, and theuse of a suitable reference spectrum. Sample dissolution is indeuterated hexafluoroisopropanol (D-HFIP) or other proton-free solvent able to fully solvate the specimen. Analysis shallbe conducted using practices similar to those described inPractice E 386

29、.5.2.3.2 Additional spectral bands may be indicative ofknown or unknown impurities, including residual solvents andcatalysts (refer to limits specified in Table 1).5.2.4 Carbon-13 Nuclear Magnetic Resonance (13C-NMR)Identification:5.2.4.1 Identity of either poly(glycolide) homopolymer orpoly(glycoli

30、de-co-lactide) copolymer may be confirmed in asolid state through13C-NMR spectroscopy and the use of asuitable reference spectrum. Analysis shall be conducted usingpractices similar to those described in Practice E 386.4Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville,MD 2085

31、2-1790, http:/www.usp.org.5Available from American National Standards Institute (ANSI), 25 W. 43rd St.,4th Floor, New York, NY 10036, http:/www.ansi.org.6Available from ICH Secretariat, c/o IFPMA, 30 rue de St-Jean, P.O. Box 758,1211 Geneva 13, Switzerland. Available online at http:/www.ich.org/LOB/

32、media/MEDIA423.pdf7Available from U.S. Government Printing Office Superintendent of Documents,732 N. Capitol St., NW, Mail Stop: SDE, Washington, DC 20401, http:/www.access.gpo.gov.8Available from National Institute of Standards and Technology (NIST), 100Bureau Dr., Stop 1070, Gaithersburg, MD 20899

33、-1070, at http:/physics.nist.gov/cuu/Units/bibliography.html.F23130812NOTESupplied example infra-red spectrum is of “Dexon Medical Suture (beige)” as acquired from the Hummel Polymer Library, available from:Thermo Nicolet Corporation, 5225 Verona Road, Madison, WI 53711-4495, USA.FIG. 1 Poly(glycoli

34、de) Resin Infrared SpectrumF23130813NOTESupplied example infra-red spectrum is of “Vicryl Medical Suture (violet)” as acquired from the Hummel Polymer Library, available from:Thermo Nicolet Corporation, 5225 Verona Road, Madison, WI 53711-4495, USA.FIG. 2 Poly(90 % glycolide-co-10 % lactide) Resin I

35、nfrared SpectrumF231308145.2.4.2 Additional spectral bands may be indicative ofknown or unknown impurities, including residual solvents andcatalysts (refer to limits specified in Table 1).5.3 Molar Mass:NOTE 1The term molecular weight (abbreviated MW) is obsolete andshould be replaced by the SI (Sys

36、tme Internationale) equivalent of eitherrelative molecular mass (Mr), which reflects the dimensionless ratio of themass of a single molecule to an atomic mass unit see ISO 31-8, or molarmass (M), which refers to the mass of a mole of a substance and istypically expressed as grams/mole. For polymers

37、and other macromol-ecules, use of the symbols Mw, Mn, and Mzcontinue, referring tomass-average molar mass, number-average molar mass, and z-averagemolar mass, respectively. For more information regarding proper utiliza-tion of SI units, see NIST Special Publication SP811.5.3.1 The molar mass of the

38、virgin polymer shall beindicated by inherent viscosity in dilute solution (IV). Inaddition to inherent viscosity (but not in place of), massaverage molar mass and molar mass distributions may bedetermined by gel permeation chromatography (GPC) accord-ing to Test Methods D 3536 or D 3593, but using h

39、exafluor-oisopropanol (HFIP) solvent and poly methylmethacrylate(PMMA) calibration standards.5.3.1.1 Determine the inherent viscosity of the polymereither in hexafluoroisopropanol (HFIP) or hexafluoroacetonesesquihydrate (HFAS) at 30C using procedures similar tothose described in Practice D 2857 and

40、 Test Method D 4603.Determination at a lower temperature of 25C is allowable,provided the utilized equipment delivers the required thermalcontrol and an experimentally supported 30C equivalentconcentration-appropriate extrapolated result is also reportedwithin the supplied certification. Note that i

41、ncomplete sampledissolution or precipitation from solution can result in forma-tion of gels and will produce inconsistency and variation inobserved drop times. Inherent viscosity is determined utilizingthe following equation:IV 5lnttov!w(1)where:IV = inherent viscosity (at 30C in dl/gram),t = efflux

42、 time in seconds for diluted solution,to= efflux time in seconds for source solvent,w = mass of polymer being diluted (in grams), andv = dilution volume in deciliters (Note: 1 dl = 100 mL).5.3.1.2 Resin concentration for IV analysis must be 0.5 %w/v or less, with resin analyte concentrations of 0.1

43、% w/v(that is, 0.001 g/mL or 1 mg/mL) recommended. Whenreporting results, identify the solvent utilized, analyte concen-tration, and analysis temperature.5.4 Residual Monomer:5.4.1 The virgin polymer shall have a combined totalresidual monomer content less than or equal to 2.0 % by mass.5.4.1.1 Dete

44、rmine mass percent residual monomer by gaschromatography,1H-NMR spectroscopy (using D-HFIP orother proton-free solvent able to fully solvate the specimen), orother suitably sensitive analytic method as agreed upon bysupplier and purchaser.5.5 Residual Solvents:5.5.1 If any solvent is utilized in any

45、 resin manufacturing orpurification step, determine residual levels of any utilizedsolvent(s) by gas chromatography or other suitable method asagreed upon by supplier and purchaser. Acceptable residuallevels of a particular solvent shall be reflective of toxicity, witha maximum acceptable limit cons

46、istent with ICH Q3C(R3).The detection limit for the chosen analytic method must beadequate to assure compliance with the applicable ICH guide-line and the determined residual(s) and applied concentrationlimit(s) shall be reported. If no ICH concentration guidelinehas been established for a utilized

47、solvent, an entry of “no ICHguidance available” will be reported in lieu of a limit.5.5.2 To minimize potential for toxic interaction of solventcombinations, cumulative Total Solvent Combination Residu-als will be limited to 1000 ppm (refer to limit specified in Table1). This limit carries the effec

48、t of allowing ICH QC3 QualityGuidelines when a single solvent system is utilized and lessthan 1000 ppm when combinations of more than one solventare utilized (regardless of individual solvent toxicity).5.6 Heavy Metals:5.6.1 Determine residual heavy metals per Method II, Chap-ter 231 of United State

49、s Pharmacopeia (USP).5.6.2 Heavy metals generally refers to divalent cations ofthe elements cadmium (Cd), copper (Cu), mercury (Hg), andlead (Pb), to the trivalent cations of antimony (Sb), arsenic(As), and bismuth (Bi), and to tetravalent (stannic) tin (Sn4+)that form complexes with sulfide under slightly acidic condi-tions.9Since stannous tin (Sn2+) can also form tin (II) sulfideand thereby carries potential to influence test results, the excessamount ascertained by alternative analytic means to be directlyattributable to both stannic and stannous tin